RD Biotech

Executive Summary

RD Biotech is a French biotechnology CRO/CDMO founded in 1990, offering comprehensive custom services from DNA to antibodies, including monoclonal and recombinant antibodies, proteins, and cell-based products. The company’s integrated platform covers development, production, purification, quality control, and analytical services, positioning it as a one-stop partner for biopharma firms seeking outsourced antibody and protein solutions. With over three decades of experience, RD Biotech has built a reputation for reliability and technical expertise, primarily serving European clients. The demand for biologics and outsourcing continues to grow, presenting opportunities for RD Biotech to expand its service offerings and geographic reach. However, the company faces competition from larger global CROs and CDMOs. Potential growth drivers include new service introductions, such as bispecific antibodies, and strategic partnerships or expansions into the US market. As a private company, financial performance is not publicly available, but its established position suggests stable operations. Near-term catalysts could enhance its competitive standing and revenue streams.

Upcoming Catalysts (preview)

• Q3 2026Launch of bispecific antibody development service70% success
• TBDUS market expansion through partnership or subsidiary50% success
• Q4 2026Achievement of ISO 13485 certification for manufacturing80% success